Collegium Pharmaceutical, Inc. Convertible Notes Payable, Noncurrent
Collegium Pharmaceutical, Inc. (COLL) had Convertible Notes Payable, Noncurrent of $238.73 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Notes and Loans, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-08-06
- 2026-06-30: Convertible Notes Payable, Noncurrent $238.73M.
- 2026-03-31: Convertible Notes Payable, Noncurrent $238.47M.
- 2025-12-31: Convertible Notes Payable, Noncurrent $238.21M.
- 2025-09-30: Convertible Notes Payable, Noncurrent $237.95M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2026-06-30 | $238.73M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $238.47M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $238.21M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $237.95M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $237.69M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $237.43M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $237.17M 10-K · filed 2026-02-26 |
| 2024-09-30 | $236.91M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $236.65M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $262.43M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $262.13M 10-K · filed 2025-02-27 |
| 2023-09-30 | $261.82M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $261.52M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $261.22M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $140.87M 10-K · filed 2024-02-22 |
| 2022-09-30 | $140.64M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $140.41M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $140.19M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $139.97M 10-K · filed 2023-02-23 |
| 2021-09-30 | $139.74M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $139.51M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $139.29M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $99.58M 10-K · filed 2022-02-24 |
| 2020-09-30 | $97.80M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $96.05M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $94.38M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |